Q&A with Anil K. Sood, MD, on Ovarian Cancer Research and Treatment

On Sunday, almost 300 of the greatest minds in ovarian cancer research will come together in Pittsburgh to discuss the latest advances in the field at the American Association for Cancer Research four-day conference on Addressing Critical Questions in Ovarian Cancer Research and Treatment.

Read More

Cultivating a More Diverse Scientific Work Force

The U.S. Latino population surged 243 percent from 1980 to 2010. But in the same time span, the Latino physician work force dropped from 135 to 105 physicians per 100,000, according to a study by the Center for the Study of Latino Health and Culture at the University of California, Los Angeles.

This decline is alarming. It means that the growing Latino population does not get culturally competent care needed to improve patient health outcomes.

Read More

How Mouse Models Pave the Way to Precision Cancer Medicine

The AACR is holding a special conference, Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond, in Orlando, Florida, September 24-27. This conference will highlight recent advances in the design and implementation of genetically engineered mouse models of cancer.

Read More

What Advances are Researchers Making in Treating Glioblastoma, McCain’s Cancer?

As we learned recently, Senator John McCain was diagnosed with glioblastoma multiforme, an aggressive form of central nervous system tumor that starts in the brain or spinal cord. It accounts for about 45 percent of all primary brain tumors, with about 11,000 diagnoses in men, women, and children each year.

Read More

Advancing Translational Cancer Medicine in Latin America

In recent years, the American Association for Cancer Research (AACR) has expanded its efforts to catalyze advances in cancer research globally and support its members residing in 107 countries in addition to the United States. One important initiative this year was the landmark conference held May 4-6, in São Paulo, Brazil—the AACR International Conference on Translational Cancer Medicine.

Read More

AACR Annual Meeting 2017: Challenging the Dogma of Treating IDH-mutant Cancers With IDH Inhibitors

Two studies presented at the AACR Annual Meeting 2017 showed that tumors that have mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to that of BRCA-mutant tumors and are, therefore, more likely to respond better to PARP inhibitors than to IDH inhibitors.

Read More

AACR Annual Meeting 2017: Most Merkel Cell Carcinoma Responses to the Newly FDA-Approved Avelumab Expected to Last More than a Year

T cells and antibodies

On March 23, the U.S. Food and Drug Administration announced the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma. The treatment, the immunotherapeutic avelumab (Bavencio), was approved based on data from the JAVELIN Merkel 200 phase II clinical trial.

Read More